<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774198</url>
  </required_header>
  <id_info>
    <org_study_id>H-17024315</org_study_id>
    <nct_id>NCT04774198</nct_id>
  </id_info>
  <brief_title>Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy</brief_title>
  <official_title>Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative immunologic signatures can predict the risk of postoperative complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE Establish evidence for perioperative immunologic risk stratification of patient's&#xD;
      risk for clinically postoperative inflammatory complications as a basis for future&#xD;
      mechanism-based intervention studies.&#xD;
&#xD;
      Combining detailed immune assessment from cell-receptors to cell expression, cytokines, and&#xD;
      complications with a temporal aspect is innovative and provides highly warranted novel&#xD;
      multidimensional immunological insight.&#xD;
&#xD;
      METHODS Adult patients scheduled for PD on the suspicion of pancreatic cancer excluding&#xD;
      patients receiving immunomodulating treatment 1 month properatively and/or autoimmune&#xD;
      diseases. Patients scheduled for simultaneous procedures on major blood vessels, and/or&#xD;
      adjacent organs (spleen, liver) are also not included. Inoperable patients, for instance, due&#xD;
      to carcinosis, circulatory/ventilatory instability hindering procedure completion and/or&#xD;
      concomitant surgery on major blood vessels, spleen, or liver, are excluded post-inclusion and&#xD;
      will not be part of the primary analysis. Patients eligible for inclusion will be identified&#xD;
      before their appointment at the Gastrosurgical Dept., Rigshospitalet which is the largest DK&#xD;
      and North-European center with about 200 PD/yr annually.&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      Persistent postoperative hypotension, defined as need for vassopressor infussion on the&#xD;
      morning after surgery to maintain middle arterial bloodpressure &gt;65 mmHg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Persistent postoperative hypotension</measure>
    <time_frame>24 hours</time_frame>
    <description>Need for vasopressor infusion (noradrenaline) to maintain middle arterial blood pressure &gt;65 mmHg, the morning after pancreaticoduodenectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>30 days</time_frame>
    <description>Ex. surgical site infection, pneumonia, sepsis, etc, based upon international criteria (eg. center for disease control)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence (yes/no) of systemic inflammatory response syndrome (SIRS) at any time during the first 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>SIRS defined as two or more of either of the following four criteria: i) temperature &lt;36°C or &gt;38°C, ii) heart rate &gt;90/min., iii) respiratory rate &gt;20/min and/or iv) white blood cell count (WBC) &lt;4x109/L (&lt;4000/mm³), &gt;12x109/L (&gt;12,000/mm³) or ≥10% bands neutrophils.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe clinical intra- and postoperatove complications</measure>
    <time_frame>30 days</time_frame>
    <description>Complications assessed by Clavien-Dindo classification and Comprehensive Clinical complication Index (CCI) ( (i.e. anastomotic leakage, reoperation, thrombosis, bleeding, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe clinical intra- and postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Complications assessed by SOFA score including single organ system deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe perioperative physiological deviations</measure>
    <time_frame>30 days</time_frame>
    <description>Frequency og physiological deviation Monitored by WARD-clinical support system (i.e hypotension, desaturation, tachycardia, etc.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of delirium after surgery</measure>
    <time_frame>7 days</time_frame>
    <description>Development of delirium measured with the 3D-CAM score</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Occurrence of persistent postoperative hypotension</arm_group_label>
    <description>Patients with need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)&gt;65 mmHg, after pancreaticoduodenectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No occurrence of persistent postoperative hypotension</arm_group_label>
    <description>Patients without need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)&gt;65 mmHg, after pancreaticoduodenectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)</description>
    <arm_group_label>No occurrence of persistent postoperative hypotension</arm_group_label>
    <arm_group_label>Occurrence of persistent postoperative hypotension</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Full blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients scheduled for PD on the suspicion of pancreatic cancer excluding patients&#xD;
        receiving immunomodulating treatment 1 month properatively and/or autoimmune diseases and&#xD;
        patients non-cenacerous cystic lessions. Patients scheduled for simultaneous procedures on&#xD;
        major arterial blood vessels, and/or adjacent organs (spleen, liver) are also not included.&#xD;
        Inoperable patients, for instance, due to carcinosis, circulatory/ventilatory instability&#xD;
        hindering procedure completion and/or concomitant surgery on major arterial blood vessels,&#xD;
        spleen, or liver, are excluded post-inclusion and will not be part of the primary analysis.&#xD;
        Patients eligible for inclusion will be identified before their appointment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for PD on the suspicion of pancreatic cancer&#xD;
&#xD;
          -  Patients able to follow standardised surgical procedure including TIVA anaesthesia&#xD;
             with epidural&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilirubin &gt;100 µmol/ltr&#xD;
&#xD;
          -  Patients receiving immunomodulating treatment 1 month properatively and/or autoimmune&#xD;
             diseases and patients non-cenacerous cystic lessions&#xD;
&#xD;
          -  Patients scheduled for simultaneous procedures on major arterial blood vessels, and/or&#xD;
             adjacent organs (spleen, liver)&#xD;
&#xD;
          -  Inoperable patients, for instance, due to carcinosis, circulatory/ventilatory&#xD;
             instability hindering procedure completion and/or concomitant surgery on major&#xD;
             arterial blood vessels, spleen, or liver, are excluded post-inclusion and will not be&#xD;
             part of the primary analysis&#xD;
&#xD;
          -  ongoing treatment with glucocortocoid, anti-tnf-alpha etc.&#xD;
&#xD;
          -  patients diagnosed with rheumatological diseases, IBD or chronic infection (eg. HIV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eske K Aasvang, DMSci</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sisse R Ostrowski, DMSci</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra T Pitter, MD</last_name>
    <phone>+4540309153</phone>
    <email>sandra_pitter@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eske K Aasvang, DMSci</last_name>
    <phone>26232076</phone>
    <email>eske.kvanner.aasvang.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra T Pitter, MD</last_name>
      <phone>+4540309153</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Eske Kvanner Aasvang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

